KOMBIGLYZE XR 500 mg/1

KOMBIGLYZE XR 500 mg/1 combines saxagliptin and metformin hydrochloride for extended-release blood sugar management. This oral medication supports glucose control in adults with type 2 diabetes.

KOMBIGLYZE XR 500 mg/1 is used to improve glycemic control in adults with type 2 diabetes. It combines saxagliptin, a DPP-4 inhibitor, and metformin hydrochloride, a biguanide, to help manage blood sugar levels. This medication is typically prescribed as part of a comprehensive diabetes management plan, which may include diet and exercise.

Common effects of KOMBIGLYZE XR 500 mg/1 may include gastrointestinal discomfort, such as nausea or diarrhea, particularly when first starting the medication. Some individuals may also experience headache or upper respiratory tract infection. These effects are generally mild and temporary, but persistent or severe symptoms should be discussed with a healthcare provider.

KOMBIGLYZE XR 500 mg/1 should be handled with care, especially for individuals with kidney or liver impairment. It is important to follow the prescribed dosage and administration instructions. Regular monitoring of blood sugar levels is recommended. Always consult a healthcare provider before starting or stopping any medication.

KOMBIGLYZE XR 500 mg/1 may interact with certain medications, including other diabetes drugs, diuretics, and some antibiotics. Alcohol consumption should be avoided as it can increase the risk of lactic acidosis. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.